Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 11/20 | 0.52 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.52 |
| ▸ | GAK | O14976 | 4/20 | 0.52 |
| ▸ | ILK | Q13418 | 2/20 | 0.52 |
| ▸ | KDM1A | O60341 | 2/20 | 0.52 |
| ▸ | PLK4 | O00444 | 1/20 | 0.52 |
| ▸ | CIT | O14578 | 1/20 | 0.52 |
| ▸ | AURKA | O14965 | 1/20 | 0.52 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.52 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.52 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.52 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.52 |
| ▸ | BUB1 | O43683 | 1/20 | 0.52 |
| ▸ | JAK2 | O60674 | 1/20 | 0.52 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.52 |
| ▸ | STK17B | O94768 | 1/20 | 0.52 |
| ▸ | STK10 | O94804 | 1/20 | 0.52 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 0.52 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.52 |
| ▸ | ABL1 | P00519 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29493193 | 1.00 | EGFR (0.52) | EGFRERBB2GAKILKKDM1A | |
| Hydrochloric Acid SCHEMBL30963337 | 0.99 | EGFR (0.52) | EGFRERBB2GAKILKKDM1A | |
| SCHEMBL16212567 | 0.94 | EGFR (0.46) | EGFRERBB2GAKILKKDM1A | |
| SCHEMBL7858883 | 0.93 | EGFR (0.49) | EGFRERBB2GAKILKKDM1A | |
| SCHEMBL642249 | 0.82 | ADORA2A (0.46) | EGFRGAKLMNAABCB1CYP3A4 | |
| Hydrochloric Acid SCHEMBL1436789 | 0.82 | EGFR (0.52) | EGFRERBB2GAKILKKDM1A | |
| SCHEMBL3154841 | 0.79 | EGFR (0.48) | EGFRERBB2GAKILKKDM1A | |
| Hydrochloric Acid SCHEMBL2839910 | 0.79 | EGFR (0.38) | EGFRGAKLMNACYP3A4ADORA2A | |
| SCHEMBL30017474 | 0.76 | PDPK1 (0.46) | KDM1AABCB1PDGFRBKITPDGFRA | |
| SCHEMBL869532 | 0.75 | ABCG2 (0.42) | LMNACYP3A4ADORA3SRCADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260000691-A1 | COMPOUNDS, METHODS, AND TREATMENTS FOR ABNORMAL SIGNALING PATHWAYS FOR PRENATAL AND POSTNATAL DEVELOPMENT | JENNINGS BARBARA BROOKE (US) | 2026-01-01 | — | — | US | disclosed |
| WO-2025136811-A1 | CHEMICAL COMPOUNDS AND USES THEREOF | IDEAYA BIOSCIENCES, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| US-20240207246-A1 | PHARMACEUTICAL COMPOSITION | KYOWA KIRIN CO., LTD. (JP) | 2024-06-27 | — | — | US | disclosed |
| WO-2024036114-A2 | COMBINATION THERAPY INCLUDING COX-2 INHIBITOR FOR THE TREATMENT OF CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-02-15 | — | — | WO | disclosed |
| EP-3609898-A1 | COMPOUNDS USEFUL AS RET INHIBITORS | Cancer Research Technology Limited (GB) | 2020-02-19 | — | — | EP | disclosed |
| EP-3523295-A1 | DEUTERATED N-(5-(2,3-DIHYDROBENZO[B][1,4]DIOXINE-6-CARBOXAMIDO)-2-FLUOROPHENYL)-2-((4-ETHYLPIPERAZIN-1 -YL)METHYL)QUINOLINE-6-CARBOXAMIDE | Cancer Research Technology Limited (GB) | 2019-08-14 | — | — | EP | disclosed |
| EP-3442980-A1 | HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | Cancer Research Technology Limited (GB) | 2019-02-20 | — | — | EP | disclosed |
| WO-2018189553-A1 | COMPOUNDS USEFUL AS RET INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-10-18 | — | — | WO | disclosed |
| WO-2018065787-A1 | DEUTERATED N-(5-(2,3-DIHYDROBENZO[B][1,4]DIOXINE-6-CARBOXAMIDO)-2-FLUOROPHENYL)-2-((4-ETHYLPIPERAZIN-1 -YL)METHYL)QUINOLINE-6-CARBOXAMIDE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-04-12 | — | — | WO | disclosed |
| US-9938268-B2 | C-ring modified tricyclic benzonaphthiridinone protein kinase inhibitors and use thereof | MERCK PATENT GMBH (DE) | 2018-04-10 | — | — | US | disclosed |
| EP-2152370-B1 | ARYL ETHER PYRIDAZINONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2011-07-06 | — | — | EP | disclosed |
| EP-2336120-A1 | Combinations containing amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors | Istituto di ricerche di Biologia Molecolare P. Angeletti S.R.L. (IT) | 2011-06-22 | — | — | EP | disclosed |
| US-20110053906-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK PATENT GMBH (DE) | 2011-03-03 | — | — | US | disclosed |
| EP-2010496-B1 | 4-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2010-08-25 | — | — | EP | disclosed |
| EP-2057140-A1 | MORPHOLINO PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF PROLIFERATIVE DISORDERS | AstraZeneca AB (SE) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008023159-A1 | MORPHOLINO PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2008-02-28 | — | — | WO | disclosed |
| WO-2007109178-A2 | INDOLE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | PHARMACYCLICS, INC. (US) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007071961-A1 | BENZAMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | WO | disclosed |
| EP-1765790-A1 | AZINE-CARBOXAMIDES AS ANTI-CANCER AGENT | AstraZeneca AB (SE) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006003378-A1 | AZINE-CARBOXAMIDES AS ANTI-CANCER AGENT | ASTRAZENECA AB (SE) | 2006-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260000691-A1 | COMPOUNDS, METHODS, AND TREATMENTS FOR ABNORMAL SIGNALING PATHWAYS FOR PRENATAL AND POSTNATAL DEVELOPMENT | PDK1, IP6K1, IP6K3 | EGFR 3208/4885ERBB2 1302/4885GAK 1172/4885 |
| US-20240207246-A1 | PHARMACEUTICAL COMPOSITION | EGFR, VEGFA, KDR | EGFR 1/4885ERBB2 8/4885GAK 1084/4885 |
| US-20110053906-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MAP4K2, MAP3K20, MAP4K1 | EGFR 815/4885ERBB2 256/4885GAK 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.